NORDHEALTH |
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 34.9 NOK | +0.87% |
|
+0.87% | +40.73% |
| May. 14 | Transcript : Nordhealth AS, Q1 2024 Earnings Call, May 14, 2024 | |
| May. 14 | Nordhealth AS Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Sales forecast by analysts have been recently revised upwards.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- The company's enterprise value to sales, at 60.31 times its current sales, is high.
- The company appears highly valued given the size of its balance sheet.
- The three month average target prices set by analysts do not offer high potential in comparison with the current prices.
Ratings chart - Surperformance
Sector: Advanced Medical Equipment & Technology
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +40.73% | 256M | - | ||
| +6.26% | 33.06B | C | ||
| +20.73% | 7.99B | C- | ||
| +33.47% | 4.34B | B- | ||
| -30.70% | 2.62B | C- | ||
| -15.76% | 1.46B | B | ||
| -25.93% | 1.31B | - | C+ | |
| -29.79% | 1.21B | - | ||
| +10.99% | 993M | C | ||
| -36.79% | 883M | - |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
-
- Stock Market
- Equities
- NORDH Stock
- Ratings Nordhealth
